Ubiquitin-like 3 as a new protein-sorting factor for small extracellular vesicles

Takanashi, Yusuke; Kahyo, Tomoaki; Kamamoto, Sae; Zhang, Hengsen; Chen, Bin; Ping, Yashuang; Mizuno, Kiyomichi; Kawase, Akikazu; Koizumi, Kei; Satou, Masanori; Funai, Kazuhito; Shiiya, N; Setou, Mitsutoshi

doi:10.1247/csf.21078

Cited by 7 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These reports seem that the UBL3 functions may be different in different cancers and at different stages of cancer. As we mentioned, regarding the hypothesis in [ 127 ], there are two possible functions played by UBL3 in cancers: UBL3 acts as a “guardian” in cells to inhibit cancer development and metastasis by collecting tumor-promoting-related factors in cancer cells and isolating these factors into sEVs. For example, MMP14 is involved in angiogenesis, extracellular matrixization, and epithelial mesenchymalization in breast cancer, pancreatic cancer, colon cancer, and sarcoma, which promote tumor invasion and metastasis [ 128 , 129 , 130 , 131 ].…”

Section: Prospectivementioning

confidence: 99%

A New Potential Therapeutic Target for Cancer in Ubiquitin-Like Proteins—UBL3

Zhang

Chen

Waliullah

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Ubiquitin-like proteins (Ubls) are involved in a variety of biological processes through the modification of proteins. Dysregulation of Ubl modifications is associated with various diseases, especially cancer. Ubiquitin-like protein 3 (UBL3), a type of Ubl, was revealed to be a key factor in the process of small extracellular vesicle (sEV) protein sorting and major histocompatibility complex class II ubiquitination. A variety of sEV proteins that affects cancer properties has been found to interact with UBL3. An increasing number of studies has implied that UBL3 expression affects cancer cell growth and cancer prognosis. In this review, we provide an overview of the relationship between various Ubls and cancers. We mainly introduce UBL3 and its functions and summarize the current findings of UBL3 and examine its potential as a therapeutic target in cancers.

show abstract

Section: Prospectivementioning

confidence: 99%

A New Potential Therapeutic Target for Cancer in Ubiquitin-Like Proteins—UBL3

Zhang

Chen

Waliullah

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…EVs are also attractive because they possess a fusion mechanism with the plasma membrane that allows them to efficiently transport substances to the cytoplasm. Currently, studies on the delivery of nucleic acid drugs such as siRNA, protein drugs, and small molecule drugs using these EVs as carriers are underway [22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Can Extracellular Vesicles as Drug Delivery Systems Be a Game Changer in Cardiac Disease?

et al. 2022

View full text Add to dashboard Cite

Cardiac diseases such as myocardial infarction and heart failure have been the leading cause of death worldwide for more than 20 years, and new treatments continue to be investigated. Heart transplantation, a curative treatment for severe cardiac dysfunction, is available to only a small number of patients due to the rarity of donors and high costs. Cardiac regenerative medicine using embryonic stem cells and induced pluripotent stem cells is expected to be a new alternative to heart transplantation, but it has problems such as induction of immune response, tumor formation, and low survival rate of transplanted cells. On the other hand, there has been a focus on cell-free therapy using extracellular vesicles (EVs) due to their high biocompatibility and target specificity. Exosomes, one type of EV, play a role in the molecular transport system in vivo and can be considered a drug delivery system (DDS) innate to all living things. Exosomes contain nucleic acids and proteins, which are transported from secretory cells to recipient cells. Molecules in exosomes are encapsulated in a lipid bilayer, which allows them to exist stably in body fluids without being affected by nuclease degradation enzymes. Therefore, the therapeutic use of exosomes as DDSs has been widely explored and is being used in clinical trials and other clinical settings. This review summarizes the current topics of EVs as DDSs in cardiac disease.

show abstract